rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.
about
Mechanism and significance of cell type-dependent neutralization of flavivirusesHuman antibody responses after dengue virus infection are highly cross-reactive to Zika virusThe dengue vaccine pipeline: Implications for the future of dengue controlNeutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic ReviewGuiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccineUnderstanding the dengue viruses and progress towards their controlVaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3′ untranslated region (3′-UTR) or by exchange of the DENV-3 3′-UTR with that of DENV-4Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeysPhase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicityPhase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4 30-4995 in Healthy Adult VolunteersVaccines and immunization strategies for dengue preventionProspects for a dengue virus vaccineIn a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccinationVero cell platform in vaccine production: moving towards cell culture-based viral vaccines.Flaviviruses, an expanding threat in public health: focus on dengue, West Nile, and Japanese encephalitis virus.A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial.The neurovirulence and neuroinvasiveness of chimeric tick-borne encephalitis/dengue virus can be attenuated by introducing defined mutations into the envelope and NS5 protein genes and the 3' non-coding region of the genome.Substitution of NS5 N-terminal domain of dengue virus type 2 RNA with type 4 domain caused impaired replication and emergence of adaptive mutants with enhanced fitness.Dengue vaccines: state of the art.Dengue vaccines: recent developments, ongoing challenges and current candidates.Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic.The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccineTargeted mutagenesis as a rational approach to dengue virus vaccine development.Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive AdultsA single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trialImmunologic hypo- or non-responder in natural dengue virus infectionDevelopment of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profilesThe live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers.A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates.Challenges in reducing dengue burden; diagnostics, control measures and vaccines.An update on Zika vaccine developments.Developing a dengue vaccine: progress and future challenges.Recent progress in dengue vaccine development.Vaccines licensed and in clinical trials for the prevention of dengue.The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model.The necessity and quandaries of dengue vaccine development.Zika vaccines and therapeutics: landscape analysis and challenges ahead.
P2860
Q23032973-141DB07F-7024-4E03-8B1C-C4FFF56C921BQ25161212-DB2B9117-5380-4448-985A-8A1F36190A0EQ26314683-5BB843E8-182F-4B82-BE74-537785333D8DQ26700078-33610323-F94A-45D3-B836-FE50743AE0B7Q26782367-4D9C9260-3165-437E-81DE-0C097E11C3E4Q27011587-13CF9DC6-1A32-4282-9FEF-7E5F8AF4E831Q27478162-7E420170-4ECC-4902-A98F-EF0930A6C564Q27485404-5B6CBE54-2BD8-4342-A88A-707C6DE06BD4Q27487013-CAEBA35C-52C9-444A-BCEA-0B40ACC6BC41Q27487377-B91AF8B3-ED31-4B7A-9BDA-113DAC7F10ECQ27490989-EEE6E08C-954F-45D9-AD44-A9CAC9C6CAB5Q28077521-C9485F0B-0284-4563-862E-FFF8A9F3C7EDQ29619608-993F453D-2580-4B54-A270-49C7650ED10BQ30250977-33969159-48F7-451E-A10A-D07B69D70254Q30376550-C2AC193C-E6C7-41CE-8D1B-DA7D581D2C28Q30857727-9051D1CF-17BB-4681-83F6-6BDAF22398C8Q33988937-CD465CB6-959F-4EF3-BC72-ABFA6918EF8FQ34036778-0B44BFE3-67F7-461B-A65F-3C5348F5C4A1Q34070463-1A9CF50B-2DCA-453B-AC33-04D78F2EC423Q34109652-A9F38B59-658C-4A52-BB0F-83913D97F855Q34367194-CD31C758-1D57-4C23-91D3-8C7EA3A12FA6Q34763787-3CF1C002-72A4-4A8D-B2BA-6001297868F5Q35069160-41A187E5-AEE8-43FF-A25D-66B37C591119Q35206695-49368E9D-B18B-4C7C-B906-CA41B31A8538Q36118259-B2D57A2F-5D44-438E-99CA-64A5E5034129Q36181531-C095F7BA-7E7A-4414-8D27-A71FAE283A12Q36607295-E67F72FC-BEB1-491B-AB91-D06C4FE52DB3Q36922684-C1E407A7-8640-4814-AD9B-0A820ABA25DCQ37115807-A0B93ACA-6E9B-4FDF-A060-AADB450FE19EQ37184768-356B7C57-CCBD-4C52-AF4D-EE7E6AABECFCQ37324444-E37C8AA5-3EAF-4CD4-A9AC-40B48085F540Q37336762-AD918086-CD85-462E-8391-421107041BE2Q38140035-F8D5CC58-6FFC-4546-A14D-6BCA7E772F90Q38158670-1AB5BD53-53F1-4CF4-A463-D31DE70C6383Q38201151-8960A500-9B33-4B35-BE82-A1597ED6664BQ38303232-630A4165-66BA-45AA-B306-D4CE5CA8BCD5Q39172722-E10AA116-1A97-443E-96F2-899CB2DB6253Q40109446-C4651AE4-B648-4A75-9D28-3F6B194413BAQ42710655-D3D947C7-A8BA-45FA-B02B-87052101850BQ55084405-F7CAE1BE-1084-439C-B6E2-33FDFBC4D658
P2860
rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
rDEN2/4Delta30(ME), a live att ...... n healthy dengue-naïve adults.
@en
type
label
rDEN2/4Delta30(ME), a live att ...... n healthy dengue-naïve adults.
@en
prefLabel
rDEN2/4Delta30(ME), a live att ...... n healthy dengue-naïve adults.
@en
P2093
P356
P1433
P1476
rDEN2/4Delta30(ME), a live att ...... n healthy dengue-naïve adults.
@en
P2093
Bhavin Thumar
Brian R Murphy
Jennifer A Marron
Joseph E Blaney
Julie H McArthur
Kimberli Wanionek
P304
P356
10.4161/HV.2.6.3494
P577
2006-11-05T00:00:00Z